UnknownPhase 4NCT03811223

Effects of Evolocumab Versus Placebo Added to Standard Lipid-lowering Therapy on Fasting and Post Fat Load Lipids in Patients With Familial Dysbetalipoproteinemia

Studying Dysbetalipoproteinemia

Last synced from ClinicalTrials.gov May 8, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: UMC Utrecht
Principal Investigator: Frank LJ Visseren, prof
UMC Utrecht
Intervention: Evolocumab Auto-Injector [Repatha](drug)
Enrollment: 30 enrolled
Eligibility: 18 years · All sexes
Timeline: 2019 – 2021

Collaborators

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · Erasmus Medical Center · University Medical Center Nijmegen

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03811223 on ClinicalTrials.gov

Other trials for Dysbetalipoproteinemia

Additional recruiting or active studies for the same condition.

RECRUITINGPHASE3NCT07219602
A Study to Evaluate the Effect of Obicetrapib/Ezetimibe 10 mg Fixed-Dose Combination or Obicetrapib 10 mg Daily on Top of Guideline-Recommended Lipid-Lowering Therapy in Participants With Type 2 Diabetes and/or Metabolic Syndrome
NewAmsterdam Pharma

See all trials for Dysbetalipoproteinemia →

← Back to all trials